300142 沃森生物
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额173,917490,9261,036,5251,133,7691,201,491
投资活动产生之现金流量净额(44,843)(316,649)(1,266,667)(807,994)(935,186)
筹资活动产生之现金流量净额(711,129)(2,584,184)(371,031)236,64494,818
汇率变动对现金及现金等价物的影响(3,216)(952)5,4132,2754,069
现金及现金等价物净增加/(减少)(585,271)(2,410,859)(595,760)564,694365,192
期初现金及现金等价物余额1,348,2443,759,1034,354,8633,790,1693,424,977
期末现金及现金等价物余额762,9731,348,2443,759,1034,354,8633,790,169